Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective population-based study of booster COVID-19 vaccination efficacy and safety
2021-005094-28Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Medical University of Vienna. Primary endpoints: Factors associated with antibody titers after third vaccination and Correlation of antibody titers before and after third vaccination. Started Oct 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-005094-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005094-28.